4-ACO DMT

Product Description

1. Classification and Chemical Overview

4-AcO-DMT (chemically designated as $3\text{-[2-(dimethylamino)ethyl]-1H-indol-4-yl acetate}$, $4\text{-acetoxy-N,N-dimethyltryptamine}$, or psilacetin) is an unlicensed synthetic indole alkaloid belonging to the substituted tryptamine chemical class. Structurally, it is the $O\text{-acetylated}$ ester analogue of psilocin ($4\text{-hydroxy-N,N-dimethyltryptamine}$, the active dephosphorylated metabolite of botanical psilocybin). The molecule possesses an empirical chemical formula of $\text{C}_{14}\text{H}_{18}\text{N}_{2}\text{O}_{2}$ and an average molecular weight of approximately $246.31\text{ g/mol}$. It features an indole bicyclic core substituted at the carbon-4 position with an acetoxy moiety ($\text{-O-CO-CH}_3$) and linked at the carbon-3 position to an ethylamine side chain terminating in two N-methyl groups.

The substance is typically synthesized as an off-white to tan crystalline powder in the form of a water-soluble fumarate, hydrochloride, or tartrate salt (most commonly 4-AcO-DMT fumarate), or as an unstable lipophilic freebase. It was originally synthesized by Albert Hofmann and Franz Troxler in the early 1960s during exploratory pharmaceutical investigations at Sandoz, but it was never commercialized or developed into a licensed medicine.

Within the United Kingdom regulatory framework, 4-AcO-DMT holds no marketing authorisation (MA) from the Medicines and Healthcare products Regulatory Agency (MHRA). It is not catalogued in the British National Formulary (BNF) and holds no recognized status as a Prescription Only Medicine (POM), Pharmacy (P) medicine, or General Sales List (GSL) drug under the Human Medicines Regulations 2012. Under the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001, 4-AcO-DMT is categorized as a Class A, Schedule 1 controlled drug. It is controlled under the generic structural definition covering tryptamines modified by substitution at the indole ring or side-chain nitrogen, and as an ester derivative of psilocin (itself a Class A substance). Distribution occurs exclusively via illicit online darknet marketplaces, grey-market “research chemical” vendors, and unregulated underground commercial channels (often dishonestly marketed as “synthetic magic mushrooms” or formulated into chocolate bars, gummies, and liquid dropper vials). These unregulated consumer preparations carry acute clinical risks, including active ingredient concentration variance, presence of toxic synthesis solvents, and microbiological contamination.

2. Mechanism of Action and Pharmacodynamics

The pharmacodynamic profile of 4-AcO-DMT is driven by its function as a semi-direct and prodrug agonist across central serotonin ($5\text{-HT}$) receptors, dominated by downstream activation of the $5\text{-HT}_{2\text{A}}$ receptor subtype:

• Deacetylation to Psilocin (Primary Prodrug Pathway): Pharmacological consensus indicates that 4-AcO-DMT acts predominantly as an acetylated prodrug to psilocin ($4\text{-OH-DMT}$). Following systemic or gastrointestinal absorption, ubiquitous serum and tissue non-specific esterases, pseudocholinesterases, and hepatic carboxyl esterases rapidly cleave the ester bond at the 4-position, deacetylating the molecule into active, unconjugated psilocin and acetic acid.

• $5\text{-HT}_{2\text{A}}$ Receptor Agonism and Cortical Desynchronisation: The liberated psilocin (and potentially intact 4-AcO-DMT to a lesser degree) binds with high affinity as a partial agonist at postsynaptic $5\text{-HT}_{2\text{A}}$ receptors localized on neocortical pyramidal neurons in layer V of the cerebral cortex. Receptor stimulation couples to the $G_{\alpha q/11}$ intracellular cascade, activating phospholipase C (PLC) and mobilizing inositol triphosphate ($\text{IP}_3$) and intracellular calcium ($Ca^{2+}$). This triggers a localized surge in cortical glutamate release, disrupting the tonic inhibitory gating of the thalamus and reducing functional connectivity within the default mode network (DMN). Clinically, this manifests as profound perceptual distortions (vivid geometric visual hallucinations, auditory shifts, synaesthesia), alterations in time perception, ego dissolution, and intense emotional lability.

• Non-Target $5\text{-HT}$ and Monoamine Interactions: In addition to $5\text{-HT}_{2\text{A}}$, the active metabolites display cross-reactivity and partial agonism at human $5\text{-HT}_{2\text{C}}$, $5\text{-HT}_{1\text{A}}$, and $5\text{-HT}_6$ receptors, alongside weak interactions with the vesicular monoamine transporter 2 (VMAT2) and trace amine-associated receptor 1 (TAAR1). It does not act as a primary monoamine releasing agent, and exhibits negligible direct affinity for dopamine $D_2$ or adrenergic receptors.

• Intrinsic Activity Hypothesis: While predominantly a prodrug, analytical receptor binding profiles suggest that intact 4-AcO-DMT may exhibit modest intrinsic affinity for specific $5\text{-HT}$ receptor subtypes prior to complete metabolic deacetylation, which users colloquially report as a faster subjective onset and slight somatic qualitative differences compared to botanical psilocybin.

3. Approved UK Clinical Indications and Therapeutic Scope

4-AcO-DMT possesses no approved clinical indications in the United Kingdom. No randomized, double-blind, multicentre Phase I–III clinical trials conforming to MHRA statutory criteria have ever evaluated 4-AcO-DMT for therapeutic safety, dosage precision, or clinical efficacy.

The National Institute for Health and Care Excellence (NICE) does not endorse, recommend, or integrate 4-AcO-DMT into any clinical management pathway. It is entirely absent from guidelines governing major depressive disorder (NG222), generalised anxiety disorder, post-traumatic stress disorder (PTSD), or substance use disorders. While licensed pharmaceutical-grade synthetic psilocybin has entered formal, regulated Phase II/III clinical trials within specialized UK academic centres under strict Home Office Schedule 1 licensing, 4-AcO-DMT remains an unauthorized, non-pharmaceutical chemical entity.

The practical application of 4-AcO-DMT is confined entirely to non-clinical illicit recreational drug abuse, grey-market “psychedelic microdosing,” and underground psychedelic-assisted psychotherapy. In these unregulated settings, it is sought for:

• Replicating the subjective perceptual and emotional effects of botanical psilocybin mushrooms with consistent chemical dosing (avoiding the natural biological potency variance of fungal carpophores).

• Inducing intense acute hallucinogenic experiences (“trips”) characterized by visual synthesis, mystical-type experiences, and introspective ideation.

• Self-directed, sub-hallucinogenic “microdosing” regimens ($1\text{ to }3\text{ mg}$) aimed at enhancing mood, divergent thinking, and executive focus.

4-AcO-DMT holds no status within the NHS drug tariff, cannot be prescribed on NHS prescription forms (FP10), and must never be procured or administered for human medicinal purposes.

4. Pharmacokinetic Profile and Metabolic Fate

Because 4-AcO-DMT is typically administered orally (capsules, tablets, infused edibles, or liquid solutions) or occasionally via nasal insufflation, its pharmacokinetic profile reflects rapid enzymatic cleavage and subsequent psilocin metabolism:

• Absorption: Following oral administration, 4-AcO-DMT salts (fumarate or HCl) are rapidly dissolved and absorbed across the gastric and upper intestinal mucosa. Onset of psychoactive effects is observed within 20 to 45 minutes post-ingestion in a fasted state, achieving peak subjective and systemic plasma concentrations ($T_{max}$) between 60 and 90 minutes. Ingestion alongside large, high-fat meals blunts and delays peak absorption.

• Distribution: Following absorption, intact 4-AcO-DMT and its de-esterified metabolite psilocin rapidly distribute throughout systemic tissues. Psilocin displays moderate lipophilicity and crosses the blood-brain barrier (BBB) via passive transcellular diffusion to access central $5\text{-HT}_{2\text{A}}$ receptor populations. Protein binding in human plasma is low to moderate (approximately $25\text{ to }35\%$). The apparent volume of distribution ($V_d$) is estimated between $1.5\text{ and }3.0\text{ L/kg}$.

• Biotransformation: In vivo clearance involves a two-step biotransformation cascade:

  • Rapid Deacetylation: Intestinal, plasma, and hepatic carboxyl esterases rapidly cleave the $O\text{-acetyl}$ ester linkage, converting 4-AcO-DMT into active psilocin ($4\text{-OH-DMT}$).

  • Phase II Conjugation and Oxidation: Liberated psilocin undergoes extensive hepatic Phase II metabolism, predominantly mediated by UDP-glucuronosyltransferase 1A10 (UGT1A10 in the gut) and UGT1A9 (in the liver) to form inactive psilocin-$O\text{-glucuronide}$ (accounting for $>80\%$ of urinary excretion). A minor fraction is oxidized by monoamine oxidase (MAO-A) and aldehyde dehydrogenase into 4-hydroxyindole-3-acetic acid (4-HIAA), with trace N-demethylation mediated by CYP2D6/CYP3A4.

• Elimination: Systemic elimination is predominantly renal. Approximately $80\text{ to }90\%$ of an administered dose is excreted in the urine within 24 hours, primarily as the inactive psilocin-$O\text{-glucuronide}$ conjugate, alongside trace unchanged psilocin ($<5\%$) and minor oxidative metabolites. The terminal elimination half-life ($t_{1/2}$) of psilocin derived from 4-AcO-DMT is approximately 1.5 to 3 hours. The duration of active clinical intoxication typically spans 4 to 7 hours, with residual neurocognitive fatiguability persisting for up to 12 to 24 hours post-dose.

5. Physiological Effects and Adverse Event Spectrum

The primary physiological effect reported in non-clinical contexts is intense central sensory alterations (visual pseudohallucinations, geometric patterning, enhanced musical appreciation), alterations in the sense of self, and mood euphoria or dysphoria. However, central and peripheral stimulation of serotonergic pathways generates a marked spectrum of acute multi-system adverse effects:

• Neuropsychiatric Disturbances (Common to Very Common, $\ge 1/100$ to $\ge 1/10$):

  • Acute panic reactions, severe terror, and feelings of impending doom (the classic “bad trip”).

  • Depersonalization, derealization, paranoia, and transient substance-induced psychosis.

  • Hallucinogen Persisting Perception Disorder (HPPD): prolonged or permanent re-emergence of geometric visual disturbances, visual snow, and afterimages long after the chemical has cleared from systemic circulation.

  • Precipitated psychiatric illness: unmasking or acceleration of underlying psychotic disorders (schizophrenia) or severe manic episodes in genetically susceptible individuals.

• Autonomic and Sympathomimetic Dysregulation (Common, $1/100$ to $<1/10$):

  • Marked bilateral pupillary dilation (mydriasis) and photophobia.

  • Transient sinus tachycardia, palpitations, and mild-to-moderate elevations in systolic and diastolic blood pressure.

  • Diaphoresis, piloerection, motor restlessness, and fine peripheral tremors.

  • Transient hyperthermia or fluctuating body temperature sensations.

• Gastrointestinal Effects (Common, $1/100$ to $<1/10$):

  • Nausea, epigastric discomfort, and transient emesis (provoked by peripheral stimulation of gastrointestinal $5\text{-HT}_3$ and $5\text{-HT}_2$ receptors).

• Severe, Emergent and Life-Threatening Hazards (Rare to Toxicological Overdose):

  • Serotonin Toxicity (Serotonin Syndrome): Concomitant ingestion with monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), or serotonergic stimulants exponentially compounds serotonergic stimulation, triggering life-threatening serotonin toxicity (hyperthermia $>39.0^\circ\text{C}$, neuromuscular clonus, hyperreflexia, autonomic collapse, and rhabdomyolysis).

  • Behavioral Trauma and Misadventure: Profound sensory distortion and acute delirium can lead to irrational, impulsive behaviors, accidental self-harm, falls from heights, or fatal trauma.

  • Unregulated Product Dosing and Adulteration: Because 4-AcO-DMT is manufactured without regulatory standards, consumer products (especially commercial “mushroom” chocolate bars or vape cartridges) frequently contain erratic, supratherapeutic doses or are contaminated with novel synthetic cannabinoids, synthetic cathinones, or unreacted synthetic reagents.

6. Contraindications, Drug Interactions, and Clinical Precautions

Given its non-approved status, potent central psychedelic pharmacology, and Class A legal scheduling, 4-AcO-DMT requires strict adherence to pharmacological contraindications and emergency harm-minimisation standards:

• Contraindications:

  • Absolute Contraindication in All Humans: The formulation is an unregulated, illicit Class A compound lacking medicinal safety clearance.

  • Concurrent Monoamine Oxidase Inhibitors (MAOIs): Absolute contraindication with pharmaceutical MAOIs (e.g., phenelzine, tranylcypromine, moclobemide, linezolid) or botanical MAOIs (e.g., Peganum harmala, Banisteriopsis caapi harmala alkaloids). Blocking oxidative deamination drastically intensifies psilocin exposure, provoking severe, life-threatening hyperpyrexia, cardiovascular crises, and serotonin syndrome.

  • Personal or Family History of Psychosis: Absolute contraindication in patients with schizophrenia, schizoaffective disorder, bipolar I disorder, or strong first-degree family history of primary psychotic illness.

  • Cardiovascular Disease: Contraindicated in uncontrolled hypertension ($>140/90\text{ mmHg}$), active coronary artery disease, recent myocardial infarction, or cardiac arrhythmias.

  • Pregnancy and Lactation: Absolute contraindication; safety, embryofetal toxicity, and teratogenic profiles are entirely uncharacterized.

  • Paediatric Population: Absolute contraindication in individuals under 18 years of age.

• Drug Interactions:

  • Serotonergic Pharmacotherapy (SSRIs, SNRIs, TCAs, Lithium): Concomitant use with SSRIs/SNRIs generally blunts the psychedelic efficacy of $5\text{-HT}_{2\text{A}}$ agonists through baseline receptor downregulation, often leading users to consume dangerously elevated doses. Concomitant use with lithium is particularly hazardous, carrying high documented risks of precipitating severe grand mal seizures and acute comatose delirium.

  • Central Nervous System Stimulants (e.g., Amfetamines, Cocaine, MDMA): Synergistically amplifies sympathomimetic outflow, exponentially increasing the risk of malignant hypertension, severe panic, hyperthermia, and cardiac arrhythmias.

  • Depressants (e.g., Alcohol, Benzodiazepines): Attenuates perceptual and emotional effects, but can exacerbate sedation, motor incoordination, and risk of accidental physical trauma.

• Clinical Precautions and Harm Minimisation:

  • Acute Emergency Management (“Red Flags”): Individuals presenting to NHS emergency departments with severe agitation, violent delirium, marked hyperthermia, or sustained tachycardia following 4-AcO-DMT exposure require immediate resuscitation (999/A&E). First-line clinical interventions include:

    • De-escalation in a quiet, low-stimulus environment with continuous calm reassurance.

    • Parenteral benzodiazepines (e.g., intravenous diazepam or lorazepam) as the primary pharmacological intervention for agitation, muscle hyperactivity, and hypertension.

    • Active external cooling for severe hyperthermia.

    • In cases of suspected severe serotonin syndrome refractory to supportive care, administration of the $5\text{-HT}_{2\text{A}}$ antagonist cyproheptadine (initial dose $12\text{ mg}$ orally/nasogastrically, followed by $2\text{ mg}$ every 2 hours as indicated).

  • Diagnostic and Toxicological Awareness: Standard automated NHS urine toxicology immunoassay screens do not detect 4-AcO-DMT or psilocin. Confirmatory identification requires targeted high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) via specialized clinical toxicology or forensic laboratories. Clinical diagnosis must be formulated based on observed toxidromic signs (mydriasis, perceptual distortions, tachycardia, agitation).

  • Product Warning and Harm Reduction: Clinicians encountering individuals who report purchasing unregulated “psilocybin” chocolate bars or vape oils must educate them that commercial products frequently contain 4-AcO-DMT or unlisted research chemicals rather than organic psilocybin. Patients must be warned of the severe unpredictable dosing risks, legal Class A penalties, and long-term psychiatric liabilities.

Additional Information